Compare VSTS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | QURE |
|---|---|---|
| Founded | 1936 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2023 | 2013 |
| Metric | VSTS | QURE |
|---|---|---|
| Price | $10.04 | $17.40 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $5.88 | ★ $45.00 |
| AVG Volume (30 Days) | 974.8K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,734,839,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | $1.67 | $200.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.98 | $8.73 |
| 52 Week High | $10.29 | $71.50 |
| Indicator | VSTS | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 80.19 | 52.12 |
| Support Level | $7.24 | $13.47 |
| Resistance Level | N/A | $18.37 |
| Average True Range (ATR) | 0.35 | 1.41 |
| MACD | 0.20 | 0.26 |
| Stochastic Oscillator | 90.54 | 70.60 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.